Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Nasal NK/T-cell lymphoma is a peculiar clinico-pathologic subtype of non-Hodgkin's lymphoma
(NHL). Although most patients present with stage I/II, only 30-60% of the patients remain
disease-free. The efficacy of the conventional anthracycline-based chemotherapy
(cyclophosphamide, doxorubicin, vincristine, prednisone [CHOPP]) has been unsatisfactory.
The optimal treatment of localized NK/T-cell lymphoma has not been defined yet. The optimal
dose, sequence, and multi-modality treatment with involved field radiotherapy still need to
be refined. This trial is to evaluate the efficacy of concurrent chemoradiotherapy with
cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized
NK/T-cell lymphoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Asan Medical Center Gyeongsang National University Hospital Korea University Anam Hospital